Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.


From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Read more about Garaizar and the TMC Venture Fund here.

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Read more about Klemp and Moleculin here.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Read more about Sutaria and ST&F here.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Read more about Jones and iCRYO here.


Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Houston biotech company aims to enhance oncology treatment of highly resistant cancers

Med tech

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

2025 Houston Innovation Awards winners revealed at annual event

The winners are...

After weeks of anticipation, the 2025 Houston Innovation Awards winners have been revealed. Finalists, judges, and VIPs from Houston's vibrant innovation community gathered on Nov. 13 at Greentown Labs for the fifth annual event.

This year, the Houston Innovation Awards recognized more than 40 finalists, with winners unveiled in 10 categories.

2025 Innovation Awards group photo Winners gather for a photo at the annual event. Courtesy photo

Finalists and winners were determined by our esteemed panel of judges, comprised of 2024 winners who represent various Houston industries, as well as InnovationMap editorial leadership. One winner was determined by the public via an online competition: Startup of the Year.

The program was emceed by Lawson Gow, Head of Houston for Greentown Labs. Sponsors included Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more.

Without further adieu, meet the 2025 Houston Innovation Awards winners:

Minority-founded Business: Mars Materials

Clean chemical manufacturing business Mars Materials is working to convert captured carbon into resources, such as carbon fiber and wastewater treatment chemicals. The company develops and produces its drop-in chemical products in Houston and uses an in-licensed process for the National Renewable Energy Lab to produce acrylonitrile, which is used to produce plastics, synthetic fibers and rubbers. The company reports that it plans to open its first commercial plant in the next 18 months.


Female-founded Business, presented by Houston Powder Coaters: March Biosciences

Houston cell therapy company March Biosciences aims to treat unaddressed challenging cancers, with its MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma, currently in Phase 2 clinical trials. The company was founded in 2021 by CEO Sarah Hein, Max Mamonkin and Malcolm Brenner and was born out of the TMC Accelerator for Cancer Therapeutics.

Energy Transition Business: Eclipse Energy

Previously known as Gold H2, Eclipse Energy converts end-of-life oil fields into low-cost, sustainable hydrogen sources. It completed its first field trial this summer, which demonstrated subsurface bio-stimulated hydrogen production. According to the company, its technology could yield up to 250 billion kilograms of low-carbon hydrogen.

Health Tech Business: Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. Last year, the company also added kidney action planning to its suite of services for patients with serious illnesses. In 2025, it announced major partnerships and integrations with Epic, Guidehealth, and others, and raised a $7 million series A.

Deep Tech Business: Persona AI

Persona AI is building modularized humanoid robots that aim to deliver continuous, round-the-clock productivity and skilled labor for "dull, dirty, dangerous, and declining" jobs. The company was founded by Houston entrepreneur Nicolaus Radford, who serves as CEO, along with CTO Jerry Pratt and COO Jide Akinyode. It raised eight figures in pre-seed funding this year and is developing its prototype of a robot-welder for Hyundai's shipbuilding division, which it plans to unveil in 2026.

Scaleup of the Year: Fervo Energy

Houston-based Fervo Energy is working to provide 24/7 carbon-free energy through the development of cost-competitive geothermal power. The company is developing its flagship Cape Station geothermal power project in Utah, which is expected to generate 400 megawatts of clean energy for the grid. The company raised $205.6 million in capital to help finance the project earlier this year and fully contracted the project's capacity with the addition of a major power purchase agreement from Shell.

Incubator/Accelerator of the Year: Greentown Labs

Climatetech incubator Greentown Labs offers its community resources and a network to climate and energy innovation startups looking to grow. The collaborative community offers members state-of-the-art prototyping labs, business resources and access to investors and corporate partners. The co-located incubator was first launched in Boston in 2011 before opening in Houston in 2021.

Startup of the Year (People's Choice): FlowCare

FlowCare is developing a period health platform that integrates smart dispensers, education, and healthcare into one system to make free, high-quality, organic period products more accessible. FlowCare is live at prominent Houston venues, including Discovery Green, Texas Medical Center, The Ion, and, most recently, Space Center Houston, helping make Houston a “period positivity” city.

Mentor of the Year, presented by Houston City College Northwest: Jason Ethier, EnergyTech Nexus

Jason Ethier is the founding partner of EnergyTech Nexus, through which he has mentored numerous startups and Innovation Awards finalists, including Geokiln, Energy AI Solutions, Capwell Services and Corrolytics. He founded Dynamo Micropower in 2011 and served as its president and CEO. He later co-founded Greentown Labs in Massachusetts and helped bring the accelerator to Houston.

2025 Trailblazer Award: Wade Pinder

Wade Pinder, founder of Product Houston, identifies as an "Ecosystem Wayseeker" and is the founder of Product Houston. A former product manager at Blinds.com, he has been deeply engaged in Houston’s startup and innovation scene since 2012. Over the years, he has supported hundreds of founders, product leaders, and community builders across the Houston area. In 2023, he was honored as Mentor of the Year in the Houston Innovation Awards.

America's first Ismaili Center set to open in Houston in December

Sneak Preview

The long-awaited Ismaili Center, Houston is set to open to the public next month. The 11-acre site has been painstakingly designed and constructed to offer indoor and outdoor public spaces for Houstonians to enjoy, connect, and engage. As the only Ismaili Center in the United States — and seventh in the world — it joins its international communities in London, Vancouver, Lisbon, Dubai, Dushanbe, and Toronto.

Nearly 20 years in the making, the Ismaili Center, Houston features a prayer hall, rotating art installations, a black box theater, a cafe, numerous social halls for weddings and other events, and nine acres of outdoor space and landscaped botanical gardens. Involved parties hope that the community will see the space as an extension of the neighboring parks along the bayou, and have included a garden entrance to the north lawn and gardens at the corner of Montrose Boulevard and Allen Parkway.

While Houston is known for its many community engagement centers, the architects and designers believe that the seamless integration of indoor and outdoor spaces sets the Ismaili Center, Houston apart from all others.

“What we know is the connections between buildings, environment, quality of life, and landscape — this is nothing new,” structural and facade engineer Hanif Kara says. “But, certainly, it’s hard to see that in other developments, particularly when they are done by developers. It’s quite difficult to find community spaces, and to see how quality of life is improved for everyone. I think we’ve all experienced that kind of hope that it will play out something like this.”

Designed by Farshid Moussavi Architecture and Nelson Byrd Woltz Landscape Architects, the remarkable 11-acre site is designed both to receive LEED Gold certification and to withstand the tests of Houston’s sometimes extreme weather conditions.

Principal architect Farshid Moussavi looks forward to seeing the Houston community utilize the space she’s worked so hard to deliver: “We’ve given the hardware to the community, now the software needs to come in. So I hope that there will be music recitals, or lectures, or book fairs, or other kinds of markets that can happen—even simultaneously. This is not an experiment, it’s the seventh in the world.”

Community welcome events are scheduled for December 12 and 13, but, until then, here are 10 features and things to know about the Ismaili Center, Houston.

What is the Ismaili Center, Houston?

“The use of the building is really meant for, or our hope, is that we are able to—on an enhanced view of what the community does today—have engagement on service projects, arts and culture, interfaith dialogue, and even just in bringing people together,” Omar Samji, Ismaili Council for the United States of America, says. “The notion of bringing people together in a place where it is easy to create connections because it’s an open space, and because it’s specifically designed to be a place where people interact and where people find commonality. Because whether you’re out in the gardens, or on the environs, or in the atrium, this enables connection.”

Who is His Highness the Aga Khan?

His Highness Prince Rahim Aga Khan V is the 50th hereditary Imam (spiritual leader) of the Shia Ismaili Muslims and a direct descendant of the Prophet Muhammad. He was educated at Philipps Academy in Andover and Brown University (Class of 1995). He became Imam in February 2025 upon the passing of his father, His Highness Prince Karim Aga Khan IV.

The Aga Khan promotes an understanding of Islam rooted in values of generosity, tolerance, pluralism, environmental stewardship, and the shared unity of humanity. He also chairs the Aga Khan Development Network (AKDN), one of the world’s largest private development agencies, which works across more than 30 countries to improve quality of life for marginalized communities regardless of faith or background.

The scale

The center stretches across an 11-acre site along Montrose Boulevard, from West Dallas to Allen Parkway. The physical building is 150,000 square feet, leaving nine acres for garden spaces on both the north and south sides of the building. The south side of the property is more formal, with gardens and community spaces that flank an 80-foot reflection pool and other water features. The gardens on the north side of the building are more informal, but densely planted and vast.

Photo by Iwan Baan

The creation

The development of the Ismaili Center was led by the Ismaili Council. It was initiated by His Highness Prince Karim Aga Khan IV (1936-2025), and completed under the leadership of his eldest son, Prince Rahim Aga Khan V.

The project was designed and constructed by a team of both local and international firms. Farshid Moussavi Architecture joined forces with structural and facade engineer Hanif Kara, co-founder and creative director of AKT II. DLR Group is the architect and engineer of record, while contractor McCarthy Building Companies built the project. Thomas Woltz, senior principal and owner of landscape architecture firm Nelson Byrd Woltz, along with principal Jeff Aten taking lead on the nine acres of garden space. The project is targeting LEED Gold certification.

The focus on native Texas plants and trees

The center will be recognized as a leading cultural asset for the City of Houston, complementing nearby institutions such as The Menil Collection, Rothko Chapel, Asia Society Texas, and the Museum of Fine Arts, Houston. While the surrounding gardens will add to the other notable Nelson Byrd Woltz projects within close proximity at Memorial Park, Rothko Chapel, and Rice University.

“We’ve been building massive projects in Houston for 12 years,” Woltz says. “We know the horticultural community in the region, and we did a deep, deep dive in ecological research to understand ‘What are the native plants of whatever region?’ It’s just baked into our process. Right when we are starting any project in Houston—right to the river. Look at the soils, ‘What are the plants appropriate to that place?’ Its solar aspect, its humidity, it’s moisture in soils, the shadow of the building.

But then, this idea of taking a section across the state of Texas, so that each of those distinct ecological regions is represented by one of the terraced gardens — so it’s very clear. It’s a diagram of the state of Texas and all of its native plants. This is functioning like a botanic garden and a repository for biodiversity — this is work in service.”

The eco-friendly exterior

The exterior of the building is clad in stone, a durable material with low embodied carbon. The stone cladding is a rainscreen over in-situ ‘fair-faced’ concrete walls, exposed on the interior to minimize additional material use. The concrete mix used has replaced 35-62 percent of Portland cement with fly ash and slag, reducing CO2 emissions by roughly 30 percent compared to standard mixes. The exterior stone rainscreen uses smaller tiles to increase the stone yield, utilizing 20-25 percent more of the irregular blocks they are cut from. This reduction in waste has also lent itself to crafting the cladding in a unique way.

The tessellation of the stone pieces changes across the building's surfaces to create different patterns on different sides of the buildings and at the corners. Relief stone tiles are used to add texture to the facades.

The space for outdoor events

The north-facing botanical gardens that will accommodate the 200-year flood plain offer a 27 foot gradient toward the building. This allowed for various levels of seating and gathering areas that culminate at an elevated terrace that will act as a stage for various events such as plays and concerts. Attendees can stretch out and enjoy the shows from an extensive lawn area that is surrounded by dense gardens of native trees and plants.

The black box theater

A 2,600-square-foot black box multipurpose space which seats 125 people is found on the second floor of the building’s west wing. It can host public events, such as exhibitions, film screenings, theatrical performances, music recitals, and other artistic programs throughout the year. It will also serve as a flexible space for teaching and learning. With acoustic isolation to surrounding spaces and the mechanical mezzanine above, it is designed to operate simultaneously without disrupting other events in the building. Design includes an upper-level control room, pipe grid, and flexible drapery and seating configurations to allow for a wide variety of programming.

The cafe

The center’s café is a 1,600-square-foot, double-height space located in the west wing (Montrose side) that opens onto an enormous terrace, offering visitors the option to enjoy their coffee or food outdoors. The terrace near the cafe is lined by an exterior wall and long, trough-style fountains that aid in noise reduction from Montrose Boulevard. The second-floor wall overlooking the Café is fully glazed, creating visual connection with the levels above.

The prayer hall

The prayer hall is 12,240 square feet, featuring a unique structural system of seven interlocking squares, formed from steel beams spanning the 115-by-115-foot open space. These beams are clad in concrete to enhance durability, beneath which lies a two-layer perforated aluminum ceiling with integrated diffused lighting. Its intricate pattern recalls the traditional jālī screens of Islamic architecture creating a soft, seemingly infinite ceiling effect, adding to the serenity of the prayer hall.

---

A version of this article first appeared on CultureMap.com

TMCi names 11 global startups to latest HealthTech Accelerator cohort

new class

Texas Medical Center Innovation has named 11 medtech startups from around the world to its latest HealthTech Accelerator cohort.

Members of the accelerator's 19th cohort will participate in the six-month program, which kicked off this month. They range from startups developing on-the-go pelvic floor monitoring to 3D-printed craniofacial and orthopedic implants. Each previously participated in TMCi's bootcamp before being selected to join the accelerator. Through the HealthTech Accelerator, founders will work closely with TMC specialists, researchers, top-tier hospital experts and seasoned advisors to help grow their companies and hone their clinical trials, intellectual property, fundraising and more.

“This cohort of startups is tackling some of today’s most pressing clinical challenges, from surgery and respiratory care to diagnostics and women’s health," Tom Luby, chief innovation officer at Texas Medical Center, said in a news release. "At TMC, we bring together the minds behind innovation—entrepreneurs, technology leaders, and strategic partners—to help emerging companies validate, scale, and deliver solutions that make a real difference for patients here and around the world. We look forward to seeing their progress and global impact through the HealthTech Accelerator and the support of our broader ecosystem.”

The 2025 HealthTech Accelerator cohort includes:

  • Houston-based Respiree, which has created an all-in-one cardiopulmonary platform with wearable sensors for respiratory monitoring that uses AI to track breathing patterns and detect early signs of distress
  • College Station-based SageSpectra, which designs an innovative patch system for real-time, remote monitoring of temperature and StO2 for assessing vascular occlusion, infection, and other surgical flap complications
  • Austin-based Dynamic Light, which has developed a non-invasive imaging technology that enables surgeons to visualize blood flow in real-time without the need for traditional dyes
  • Bangkok, Thailand-based OsseoLabs, which develops AI-assisted, 3D-printed patient-specific implants for craniofacial and orthopedic surgeries
  • Sydney, Australia-based Roam Technologies, which has developed a portable oxygen therapy system (JUNO) that provides real-time oxygen delivery optimization for patients with chronic conditions
  • OptiLung, which develops 3D-printed extracorporeal blood oxygenation devices designed to optimize blood flow and reduce complications
  • Bengaluru, India-based Dozee, which has created a smart remote patient monitor platform that uses under-the-mattress bed sensors to capture vital signs through continuous monitoring
  • Montclair, New Jersey-based Endomedix, which has developed a biosurgical fast-acting absorbable hemostat designed to eliminate the risk of paralysis and reoperation due to device swelling
  • Williston, Vermont-based Xander Medical, which has designed a biomechanical innovation that addresses the complications and cost burdens associated with the current methods of removing stripped and broken surgical screws
  • Salt Lake City, Utah-based Freyya, which has developed an on-the-go pelvic floor monitoring and feedback device for people with pelvic floor dysfunction
  • The Netherlands-based Scinvivo, which has developed optical imaging catheters for bladder cancer diagnostics